GSK(US:GSK) 智通财经网·2026-02-25 08:52Core Viewpoint - GlaxoSmithKline (GSK) has agreed to acquire 35Pharma Inc. for $950 million in cash, marking its expansion into the cardiovascular drug sector [1] Group 1: Acquisition Details - The acquisition involves a biotechnology company that possesses early-stage hypertension drug assets [1] - This transaction signifies a strategic transformation for GSK, which previously had a limited pipeline for drugs targeting heart and metabolic system diseases [1] Group 2: Strategic Context - GSK's new CEO, Luke Mills, is under pressure to increase the new drug pipeline to offset the impact of patent expirations on a key HIV drug [1] - The financial pressure on GSK primarily stems from its flagship HIV drug, Dovato, which is expected to face patent expiration around 2028 [1] Group 3: Recent Acquisitions - On January 20, GSK announced the acquisition of RAPT Therapeutics, a U.S.-listed pharmaceutical company [1] - RAPT's core asset is a long-acting anti-IgE monoclonal antibody, JYB1904, which is intended for the treatment of food allergies, chronic spontaneous urticaria, and asthma [1]